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ABSTRACT 
 
Xiaomeng You: Interaction of dietary fat types and gut microbiome on modulation of whole 
body energy balance  
(Under the direction of Steven H Zeisel) 
 
                Dietary fats and gut microbes are regarded as environmental factors for the onset of obesity. 
However, whether there is a direct association between dietary fat type and gut microbiome that 
promotes obesity remains unclear. In this study, we tested the effect of modulation of the gut 
microbiome by antibiotics on energy balance in Sprague Dawley rats fed a 45% high fat diet containing 
primarily saturated fatty acids (SFA) vs. polyunsaturated fatty acids (PUFA). Antibiotic treatment 
successfully decreased the gut microbiome as evidenced by decreased microbiome α-diversity and β-
diversity. We found that food intake was decreased by antibiotic treatment irrespective diet. PUFA-fed 
rats gained less weight and consumed less food than those fed SFA independent of microbiome 
composition. No differences were seen in energy expenditure among the 4 groups. Gut hormone and 
adipokine gene and protein expression was measured in ileum, colon, white adipose tissue (WAT) and 
blood serum. Compared with SFA, PUFA fed rats had less ileum peptide YY , colon glucagon-like peptide-
1, WAT sterol regulatory element binding transcription factor 1 and more ileum β-defensins, WAT 
adiponectin gene expression. However, no differences were seen in serum protein expression among 
the 4 groups. In conclusion, SFA are more obesogenic and promote food intake as compared to PUFA 
and this positive energy balance is independent of the gut microbiome. The mechanisms by which SFA 
modulate body weight and food intake warrant further investigation.
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CHAPTER 1: BACKGROUND 
Introduction 
                Obesity is a serious public health concern all over the world. According to a World Health 
Organization (WHO) report, the incidence of obesity has doubled or even tripled in many countries over 
the past 30 years [1]. Obesity lies at the root of many prevalent metabolic disorders and diseases such as 
type 2 diabetes, cardiovascular disease, high blood pressure, dyslipidemia and cancer. Despite the fact 
that more than 300,000 deaths every year in the United States are due to obesity or its related 
metabolic disease, obesity is still one of the 10 most preventable health risks according to WHO [2]. 
Obesity results from energy imbalance and involves various mechanisms and factors including brain 
control, peripheral signals, gut immune system, and as well as dietary fats, discussed as followed.  
Central control of energy balance 
                The core principle causing obesity is energy imbalance because food intake is greater than 
energy expenditure. Physiologically, food intake and energy expenditure are tightly regulated through a 
multi-level system that connects the brain, peripheral tissues (i.e gut, fat tissue, liver, pancreas), and 
hormonal and neural signals. The brain integrates neural afferents and hormonal signals from the 
periphery received by hypothalamus and brainstem with energetic needs or anticipated needs, physical 
and social environmental factors, memory for past experiences, and many other factors to regulate 
appetite and energy expenditure (Figure 1) [3, 4].  
                The hypothalamus has been a research hotspot in obesity, as this area contains numerous 
interacting systems that regulate feeding, satiety, and other motivational states [5]. Electrical lesion and
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electrical stimulation studies have demonstrated that the lateral hypothalamus (LH) is a feeding center , 
the ventromedial hypothalamus (VMH) is a satiety center, and the arcuate nucleus (ARC) is an 
integrated center for feeding regulation [6]. The ARC contains two populations of neurons with opposing 
effects on food intake: orexigenic and anorexigenic neurons. Orexigenic neurons express neuropeptide Y 
(NPY) and Agouti-related protein (AgRP). Anorexigenic neurons express alpha-melanocyte-stimulating 
hormone (α-MSH) which is derived from pro-opiomelanocortin (POMC), and cocaine and amphetamine 
regulated transcript (CART) [3]. Circulating signals related to energy status are able to influence the 
activity of the ARC neurons directly via the underlying median eminence, as this region of the brain is 
not protected by the blood–brain barrier [3]. These ARC neurons then in turn project to a number of 
extra-hypothalamic and intra-hypothalamic regions. These areas contain secondary neurons which 
process the information regarding energy homeostasis.  
                The melanocortin 4 receptor (MC4R) plays an important role in the downstream pathway of 
hypothalamus required to modulate short-term and long-term energy homeostasis by integrating 
signals provided by α-MSH and AgRP [7, 8]. MC4R is expressed primarily in the central nervous system 
(CNS). Its mRNA was found in multiple sites in virtually every brain region, including the hypothalamus, 
brainstem, cortex, thalamus, and spinal cord [9]. Particularly, MC4R is expressed in ARC, VMH and PVN 
which are implicated in energy homeostasis [4]. Rodents studies showed that functional loss of MC4R 
increased body weight, food intake and white adipose mass [8]. Administration of agonists to the 
hypothalamic MC4R suppressed food intake, stimulated the thyroid axis and increased energy 
expenditure. Therefore, MC4R agonists are regarded as a target for obesity therapy.  
Peripheral signals of energy balance 
                To date about 100 unique molecules have been identified to have effects on energy balance [5].  
These include satiation signals that are released from the gastrointestinal tract and related organs, and 
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adiposity signals whose secretion is proportional to body fat [10]. Leptin, adiponectin, insulin, glucagon 
and gut hormones will be discussed in detail as followed.  
                Leptin is a hormone discovered in 1994 that is predominantly produced by adipose tissue [11]. 
Dietary factors and other hormones are thought to influence its secretion. In vitro, insulin is shown to 
simulate leptin secretion in adipocytes [12]. In addition, the rate of glucose uptake into adipose tissue 
determines changes in circulating leptin [13]. Other nurients might also influence leptin production. 
Rodent studies showed that diets rich in n-6 PUFA increase leptin production [14, 15]. Lack of leptin or 
leptin receptor bioactivity is responsible for a phenotype characterized by hyperphagia, reduced energy 
expenditure, and severe obesity in both rodents (ob/ob mice and db/db mice) and human [16-18]. 
Leptin is expressed and secreted in proportion to adipose mass and circulates in plasma in a 
concentration highly correlated to body fat mass [19]. The circulating leptin crosses the blood brain 
barrier, binds to leptin receptors on neurons throughout the hypothalamus and provides a negative 
feedback signal to inhibit food intake and to stimulate energy expenditure [11]. However, the rise in 
endogenous leptin, or exogenous leptin given as treatment is unable to prevent weight gain in most 
obese humans, a process called “leptin resistance” [20]. Leptin resistance may result from a decrease in 
brain transport or attenuation of leptin signaling in the hypothalamus and other central nervous system 
targets [21]. Further studies will need to focus on developing therapies aimed at reversing leptin 
resistance.  
                Adiponectin is specifically and abundantly expressed in adipocytes. Epidemiological evidence 
has indicated that circulating adiponectin levels are reduced in obese patients [22]. Adiponectin acts in 
an autocrine/paracrine manner within adipose tissue, and in an endocrine manner on distal tissues [23]. 
As an autocrine/paracrine factor in adipose tissue, adiponectin has shown beneficial effects on insulin 
sensitivity by evidence that adiponectin increased insulin's ability to maximally stimulate glucose uptake 
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by 78% through increased glucose transporter 4 (GLUT4) gene expression and increased GLUT4 
recruitment to the plasma membrane.[24] Adiponectin also functions as an endocrine factor, influencing 
whole-body metabolism via effects on target organs [23]. Adiponectin receptor 1 (Adipor1) expression is 
ubiquitous in the rat brain and adiponectin receptor 2 (Adipor2) expression is more limited to 
hypothalamus [25]. By binding to the adiponectin receptors in hypothalamus, adiponectin increases 
hypothalamic AMP-activated protein kinase (AMPK) phosphorylation to stimulate food intake and 
suppress energy expenditure [26]. However, it should be noted that intracerebroventricular 
administration of adiponectin decreased body weight with increasing energy expenditure suggesting a 
negative regulation pathway for adiponectin effect on energy balance [27]. 
                Insulin is secreted from β-cells of the pancreas. The best known action of insulin is to suppress 
the synthesis and secretion of glucose by the liver and as a result, reduce the blood glucose level. Levels 
of insulin are determined to a great extent by peripheral insulin sensitivity, and this is related to total 
body fat stores and fat distribution, with visceral fat being a key determinant of insulin sensitivity [28, 
29]. Therefore, insulin may convey a signal indicating the degree of adiposity to any insulin-sensitive 
tissue, providing a key negative feedback signal in the regulation of body fat. It is now generally 
accepted that some plasma insulin can be transported into the brain and especially to hypothalamus to 
reduce food intake and decrease body weight [30]. Insulin may cross the blood–brain barrier via a 
saturable, receptor-mediated process, at levels which are proportional to the circulating insulin [31]. 
Selective decrease in hypothalamic insulin receptor protein by antisense oligodeoxynucleotide against 
the insulin receptor precursor protein results in hyperphagia and increased fat mass indicating that 
peripheral insulin acts on hypothalamic nuclei to control energy homeostasis [32]. 
                Glucagon is a pancreatic hormone produced from the preproglucagon precursor molecule by 
the α cells of the pancreas. Its main effect is to maintain blood glucose levels during fasting and exercise 
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by promoting hepatic glycogenolysis and gluconeogenesis. Thus, the major metabolic functions of 
glucagon are opposite to those of insulin. In addition, glucagon has anorectic properties and promotes 
satiety. Peripherally administered glucagon decreased food intake and increased c-fos expression in the 
brainstem and amygdala indicating that neurons in the brainstem and amygdala are activated in order 
to reduce food intake by glucagon [33]. However, the underlying mechanism for how glucagon activates 
neurons in brain to reduce food intake is unknown. The anorectic effect following glucagon 
administration is blunted in vagotomized animals suggesting this effect is influenced by vagal input [34, 
35]. Also, low levels of glucagon receptor mRNA are found in the hypothalamus and brainstem in 
rodents indicating the possibility of direct glucagon action in these areas to reduce food intake [36]. 
                Gut hormones are peptides that are synthesized and released from the gastrointestinal tract 
[37]. There are at least 15 different types of enteroendocreine cells diffusely distributed throughout the 
gastrointestinal epithelium making the gut the most largest endocrine organ in the body [38]. Contrary 
to long-acting adiposity signals of leptin and adiponectin, the appetite hormones from gut interact with 
receptors at various points in the "gut-brain axis" to affect short-term and intermediate-term feelings of 
hunger and satiety [39]. Evidence showed that endocrine cells can directly sense luminal contents 
primarily by G protein coupled receptors (GPCRs) [40] (see Table 1). For example, L cells express the 
complete range of fatty acid receptors that can sense fats in the intestine lumen and release peptide YY 
(PYY) and glucagon-like peptide-1 (GLP-1) into circulation with effect on the hypothalamus to regulate 
energy balance [41]. To date, the gastrointestinal (GI) tract releases at least 20 different regulatory 
peptide hormones at the same time depending on the quality and quantity of the diet and influences 
various physiological processes [40, 42]. A number of gut hormones have been identified as being 
involved in appetite control and energy balance. Among them, ghrelin is called “hunger hormone” which 
is the only known circulating orexigen principally synthesized in endocrine A(X-like) cells (or ghrelin cells) 
in the stomach [43, 44]. On the contrary, other gut appetite hormones are believed to reduce food 
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intake by decreasing hypothalamic orexigenic signaling and increasing anorectic signaling (Listed in Table 
1). As gut hormones have been shown to have a fundamental role in energy homeostasis, the use of gut 
hormones as anti-obesity treatments is an attractive option and shows considerable promise.  
Endocrine-Immune interaction in gut  
                Intestinal epithelial cells act as the interface between the external environment and the 
internal milieu. The content of the intestine is rich in nutrients, chemicals and microorganisms. The gut 
processes a range of sensory systems to detect nutrients and defend against pathogens and injurious 
chemicals [40]. As discussed previously, the gut functions as an endocrine organ to release gut 
hormones by nutrients receptors that can act on other cells locally, or organs at remote sites including 
pancreatic islets and the CNS to regulate food intake, gastric empting and intestinal transit, release of 
digestive enzymes, induction of nutrient transporters and digestive enzymes, pancreatic insulin 
secretion [40].  
                Also, the gut functions to defend against pathogens and injurious chemicals. In addition to be a 
physical barrier against infection by the wealth of opportunistic pathogens that can invade through the 
oral-enteric route, intestine serves as an active immune site including adaptive immunity that 
lymphocyte mediated secretion of specific antibodies and innate immune response of secretion of non-
antigen specific compounds [45]. Intestinal epithelium constantly monitors both the luminal and 
mucosal environments through receptor mediated interactions with the contents therein [46]. In 
response to the activation of Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain 
receptors (NOD) expressed by intestinal epithelial cells, Paneth cells, and neutrophils, antimicrobial 
defence molecules (ADMs) are released as endogenous antibiotics, which are central to both the innate 
and adaptive arm of mucosal host defense within the gut [46]. Defensins are one of the major classes of 
ADMs in the intestine, which are small (2-6kDa), cationic peptides that kill bacteria primarily by 
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disruption of cell walls. Defensins are classified as α-defensins and β-defensins based on their molecular 
distribution of cysteine amino acids and the resulting disulfide bonds [47]. Recent work showed that β-
defensins can bind to the MC4R to control feeding and body weight [48]. Intracerebroventricular 
injection of human β-defensin 3 (HBD3) to male Wistar rats had an inhibitory effect on both the food 
intake and body weight gain with the potential mechanism of blocking AgRP [49]. As the secretion in 
response to bacteria in the intestine, β-defensins link the gut microbiome, intestine immunity and 
energy balance together and provide a crosstalk between gut microbiome and obesity.  
The potential mechanism linking gut microbiome to obesity 
                The gut microbiome presents more than 1,000 different molecular species or phylotypes and 
90% of the species belong to Firmicutes and Bacteroidetes [50]. Recent work has identified a role for 
microbiota in the onset of obesity. The link between microbiota and obesity was first uncovered based 
on the observation that germ-free mice contained 42% less body fat than conventional mice regardless 
of more food intake [51]. Similarly, pseudo-germ-free mice treated with an ampicillin-neomycin cocktail 
are prevented from the development of obesity when fed on a high fat diet, indicating an essential role 
for gut microbiota in obesity development [52]. Today the gut microbiota is considered a “microbial 
organ” and many studies explore the potential mechanisms of the effect of gut microbiome on host 
metabolism and its contribution to obesity.  
                Low-grade inflammation is a common comorbidity of obesity and its related metabolic 
disorder. Lipopolysaccharides (LPS) originating from gram-negative bacteria in the gut is believed to 
induce subclinical inflammation and insulin resistance and contribute to obesity [53]. In a study of 
genetically identical male rats, infusing a low level of LPS for 4 weeks caused the same amount of weight 
gain as a high-fat diet [53]. Also, rats lacking CD14, which is necessary to cause an inflammatory reaction 
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to LPS, are resistant weight gain [53]. Gut microbiota modulated by antibiotics can reduce circulating LPS 
levels, decrease inflammatory signaling and improve insulin signaling [54].  
                Increasing energy harvest from dietary fibers by gut microbiota is also believed to affect body 
weight. It is calculated that the intestinal microbiota breaks down indigestible polysaccharides (i.e., fiber) 
to short-chain fatty acids (SCFAs) providing 80 to 200 kcal per day or about 4–10% of daily energy intake 
in normal adults [55]. Also, it is proposed that the microbiota of obese individuals may be more efficient 
at extracting energy from a given diet than the microbiota of lean individuals. Lean mice have less short-
chain fatty acids in the caeca and excrete more energy by feces, compared with obese mice [56].  
                Fasting-induced adipose factor (Fiaf, also referred as Angiopoietin-like 4; ANGPTL4) is a 
secreted factor involved in regulation of lipid homeostasis by inhibiting lipoprotein lipase [57]. Germ-
free mice express excessive Fiaf in the intestine[51], which blocked the disassociation of fatty acids from 
triglycerides for uptake into tissues and upregulated fatty acid oxidation and uncoupling proteins, and 
reduced the amount of fat storage [57].  Also, germ-free mice lacking Fiaf respond to a high fat diet with 
excessive weight gain [58]. Therefore, Fiaf might serve as a circulating mediator between the gut 
microbiota and fat storage in adipose tissue.  
                The activation of AMPK is also thought to be involved in linking the gut microbiome and 
obesity, with evidence showing that germ-free mice increased skeletal muscle and liver levels of 
phosphorylated AMPK and its downstream targets involved in fatty acid oxidation [58].  
                These complementary but independent mechanisms indicate that gut microbiota may be a 
target for treating obesity. However, the effect of the gut microbiome on food intake and energy 
expenditure, the two key factors determine energy balance, are inconclusive with controversial results 
due to the different types of animals, the quality of the diet, the period of observation and the sample 
size in different studies [55].  
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The effect of dietary fat types on obesity 
                The effect of dietary fats on human health depends not only on the quantity of ingested fats, 
but also on the composition and nature of the fatty acids. Depending on the presence of double bonds, 
fatty acids are classified into three main groups: 1) saturated fatty acids (SFA) that do not contain double 
bonds 2) monounsaturated fatty acids (MUFA) that contain only one double bond, and 3) 
polyunsaturated fatty acids (PUFA) that contain at least two double bonds. Among PUFA, linoleic acid 
(LA: 18:2 n-6) and alpha-linolenic acid (ALA: 18:3 n-3), are known as essential fatty acids (EFA). They are 
fundamental for the organism, but they cannot be synthesized in the human body and must be obtained 
from the diet. Essential biological functions have been attributed to EFA-derivatives, such as arachidonic 
acid (AA, 20:4 n-6), docosahexaenoic acid (DHA, 22: 6 n-3) and eicosapentaenoic acid (EPA, 20:5 n-3) 
[59].  
                SFA derive primarily from animal sources, such as fatty meats (pork, beef, veal, lamb, ham), 
eggs and dairy products (whole milk, cream, butter and cheese) [60]. Some vegetable products (such as 
coconut oil, and palm kernel oil) are also rich in SFA [60]. PUFA are present in many species of nuts, 
vegetable oils and fish oil. In particular, n-6 PUFA are abundantly present in corn oil, cotton seed oil, 
peanut oil, soybean oil, sunflower oil and safflower oil, while canola oil, linseed oil and fish oil are rich in 
n-3 PUFA [59].  
                Generally, saturated fat of mammalian origin seems to be far more harmful to human health 
than unsaturated fat from plants and fish. SFA are associated with an increased risk various diseases 
including dyslipidemia, coronary heart disease, and cancer [61-63]. In contrast, a considerable number 
of studies have demonstrated the beneficial effects of PUFA on health [60, 64-68].  
                In many cases, n-3 PUFA and n-6 PUFA can compensate each other’s function in ameliorating 
pathological conditions such as growth retardation [59] and in the regulation of lipid raft function [59]. 
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In other situations, n-3 PUFA and n-6 PUFA have competitive functions. For example, ingestion of EPA 
and DHA from fish or fish oil replaces AA from membrane phospholipids in practically all cells, especially 
those of platelets, erythrocytes, neutrophils, monocytes and liver cells [69].  
                The balance of n-6 PUFA and n-3 PUFA is very important for homeostasis and normal 
development. Because of the increased amount of n-6 PUFA in the Western diet (n-6 PUFA to n-3 PUFA 
is about 15/1 to 16.7/1) [70], the eicosanoid metabolic products from AA are formed in larger quantities 
than those formed from n-3 PUFA. The eicosanoids from AA are biologically active in small quantities. 
However, if formed in large amounts, they will contribute to the formation of thrombi and 
atherosclerosis, the development of allergic and inflammatory disorders, and cell proliferation [69]. On 
the contrary, ingestion of EPA and DHA leads to a more physiologic state characterized by the 
production of prostanoids and leukotrienes that have antithrombotic, antichemotactic, 
antivasoconstrictive and anti-inflammatory properties [69]. 
                A high-fat diet (≥40 % of energy from fat sources) is regarded as one of the factors associated 
with the current obesity epidemic as it contributes to a positive energy balance and a positive fat 
balance as well [71]. In the meantime, it is well established that the consumption of different types of 
fat is associated with different rates of weight gain in obese animals [72]. It is believed that SFA are 
more obesogenic than PUFA [73-75], although there are controversies [76]. Early studies showed that 
animals fed with PUFA (from corn oil) have lower weight gain than SFA (from beef tallow) [77]. The 
observed difference in weight gain might be explained by the differences in capacity to control appetite 
or effects on energy expenditure. Human studies demonstrated that PUFA may exert a relatively 
stronger control over appetite than SFA [74]. A diet rich in PUFA also results in increased energy 
expenditure with preferential stimulation of the thermogenic activity of brown adipose tissue[77] and 
diet-induced thermogenesis (DIT) [72].  
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                In addition, PUFA are oxidized more rapidly than SFA, and as a result, decrease serum 
triacylglycerol level and fat accumulation [78, 79]. In rats, the consumption of a PUFA rich (from 
safflower oil) diet results in a higher lipoprotein lipase activity in heart and skeletal muscle than does a 
SFA diet (from beef tallow) [79]. Compared to SFA, PUFA (both the n-6 and n-3 series, but n-3 PUFA are 
more potent ligands for nuclear receptors than n−6 PUFA) are regarded as the preferred activator of 
peroxisome proliferator-activated receptors delta, gamma and alpha (PPAR-δ, PPAR-γ and PPAR-α) [59, 
80]. More PPAR signaling is able to up-regulate the expression of enzymes involved in conversion of 
fatty acids to acyl-coenzyme A esters, fatty acid entry into mitochondria and peroxisomal and 
mitochondrial fatty acid catabolism [81]. In addition, PUFA (both the n-6 and n-3 series, but n-3 PUFA 
are more potent ligands for nuclear receptors than n−6 PUFA) selectively decreases sterol regulatory 
element-binding protein 1 (SREBP-1), which is involved in the transcriptional regulation of lipogenic 
enzymes [59, 80, 82].  
                Recent studies show that dietary fats also affect the populations of gut microbes and their 
metabolic end products. A high-fat-fed animal displays a significant shift in both bacterial and 
metagenomic profiles as compared to an animal on a normal, chow diet [83]. Western diet-associated 
cecal microbiota are characterized by a reduction in Bacteroidetes and an increase in Firmicutes [83]. 
Animal studies also showed that the composition of the murine gut microbiome was determined by a 
high-fat diet independent of obesity [84]. Hildebrandt et al. found that a high-fat diet was associated 
with murine gut microbiome alterations characterized by a decrease in Bacteroidetes and an increase in 
both Firmicutes and Proteobacteria in the presence and absence of obesity [84]. Thus, gut microbiome 
provides another mechanism that connects dietary fats and obesity. However, a direct connection 
between a specific type of fats and gut microbes contributing to obesity remains unclear.  
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Hypothesis 
                In this study, we tested the effect of modulation of the gut microbiome by antibiotics 
on energy balance in Sprague Dawley rats fed a 45% high fat diet containing primarily saturated 
fatty acids SFA vs. PUFA as the main source of lipids. The rats within these two dietary groups 
were then treated with either an antibiotics or a vehicle to modulate the microbiome. We 
hypothesized that rats fed with a PUFA diet would have less weight gain than those fed a SFA 
diet due to less food intake and more energy expenditure due to the modulation of peripheral 
energy balance signaling from the gut, adipose tissue, and pancreas to the brain independent of 
the gut microbiome. The difference of weight gain would be seen between SFA diet and PUFA 
diet when gut microbiome is modulated by antibiotics.  
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Figure 1 Brain control of energy balance overview. (Adapted from [4]) 
The brain integrates neural afferents and hormonal signals from the periphery received by 
hypothalamus and brainstem with energetic needs or anticipated needs, physical and social 
environmental factors, memory for past experiences, and many others to regulate appetite and 
energy expenditure.  
Abbreviation: ME, median eminence; ARC, arcuate nucleus; VMH, ventromedial hypothalamus; 
DMH, dorsomedial hypothalamus; PVN, paraventricular nucleus; PFA, perifornical area; LHA, 
lateral hypothalamus; NAc, nucleus accumbens; AP, area postrema; NTS, nucleus of the solitary 
tract
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Figure 2 The ARC and the control of energy balance. (Adapted from [4]) 
The ARC contains two populations of neurons with opposing effects on food intake: orexigenic 
and anorexigenic neurons. Orexigenic neurons express neuropeptide Y (NPY) and Agouti-related 
protein (AgRP). Anorexigenic neurons express alpha-melanocyte-stimulating hormone (α-MSH) 
which is derived from pro-opiomelanocortin (POMC), and cocaine and amphetamine regulated 
transcript (CART). Circulating signals of energy status come across the median eminence to 
influence the activity of the ARC neurons directly. The ARC neurons then in turn project to a 
number of extra-hypothalamic and intra-hypothalamic regions. These areas contain secondary 
neurons which process the information regarding energy homeostasis.  
Abbreviation: α-MSH, α-melanocyte-stimulating hormone; GHS-R, growth hormone 
secretagogue receptor; CART, cocaine and amphetamine regulated transcript; NPY, 
neuropeptide Y; AgRP, agouti-related protein; Y2, neuropeptide Y receptor type 2; MC3/4, 
Melanocortin 3/4 receptor; Y1/5, neuropeptide Y receptor type 1/type 5  
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Table 1 Gut hormones on appetite control (Summarized from [37, 40, 42, 85]) 
Gut hormone Cell Luminal 
receptors* 
Locations Effect on food 
intake 
Ghrelin A(X)-like cells T1R1-T1R3; T2Rs Stomach Increase  
Cholecystokinin 
(CCK) 
I cells T2Rs; FFAR1; 
GPR120; LPAR5; 
CaSR; TRPA1; TLRs 
Proximal small 
intestine 
Decrease 
Glucose-
dependent 
insulinotropic 
polypeptide (GIP) 
K cells GPR119; GPR120; 
FFAR1 
Proximal small 
intestine 
Decrease 
Peptide YY (PYY) L cells T2Rs; T1R2-T1R3; 
FFARs 1-3; 
GPR119, LPAR5, 
GPR120; CaSR 
Distal small 
intestine and 
colon 
Decrease 
Glucagon-like 
peptide-1 (GLP-1) 
L cells T2Rs; T1R2-T1R3; 
FFARs 1-3; 
GPR119, LPAR5, 
GPR120; CaSR 
Distal small 
intestine and 
colon 
Decrease 
Glucagon-like 
peptide-2 (GLP-2)  
L cells T2Rs; T1R2-T1R3; 
FFARs 1-3; 
GPR119, LPAR5, 
GPR120; CaSR 
Distal small 
intestine and 
colon 
Decrease 
Oxyntomodulin 
(OXM) 
L cells T2Rs; T1R2-T1R3; 
FFARs 1-3; 
GPR119, LPAR5, 
GPR120; CaSR 
Distal small 
intestine and 
colon 
Decrease 
 
* Luminal receptors: T1R1-T1R3, amino acids, the umami (savoury) receptor; T1R2-T1R3, simple 
sugars and artificial sweeteners, the sweet taste receptor; T2Rs, the bitter receptor family; 
FFAR1 (also known as GPR40), free fatty acid receptor 1; FFAR2(also known as GPR43), free fatty 
acid receptor 2; FFAR3 (also known as GPR41), free fatty acid receptor 3; GPR120, G protein-
coupled receptor 120;  GPR119, G protein-coupled receptor 119; LPAR5(also known as GPR92 
and GPR93), lysophosphatidic acid receptor 5; CaSR, calcium-sensing receptor; TRPA1, transient 
receptor potential cation channel, subfamily A, member 1; TLRs, toll-like receptors;  
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CHAPTER 2: MANUSCRIPT1 
Introduction 
                Obesity is a serious public health concern. According to a 2012 World Health Organization 
(WHO) report, the incidence of obesity has doubled or even tripled in many countries over the past 30 
years [1]. Obesity lies at the root of many prevalent metabolic disorders and diseases such as type 2 
diabetes, cardiovascular disease, high blood pressure, dyslipidemia and cancer. Despite the fact that 
more than 300,000 deaths every year in the United States are due to obesity or its related metabolic 
disease, obesity is still one of the 10 most preventable health risks according to WHO [2].  
                Obesity results from energy imbalance. The control of energy balance relies upon the brain to 
detect and integrate of peripheral signals from gut, adipose tissues, pancreas of energy homeostasis and 
social, emotional, circadian, habitual and other situational factors [3, 4].   
                Recent work has identified a role for gut microbiota in the onset of obesity. The potential 
mechanisms of the effect of gut microbiota on the host metabolism, and its contribution to obesity, 
include lipopolysaccharides (LPS)- induced low grade inflammation[54], increased energy harvesting 
from dietary fibres [56], decreased fasting-induced adipose factor expression [51], changed lipid 
metabolism [51], and/or decreased AMP-activated protein kinase (AMPK) activation [58]. However, the 
effect of the gut microbiome on food intake and energy expenditure, the two key factors determine 
energy balance, are inconclusive with controversial results due to the different type of animals, the 
quality of the diet, the period of observation and the sample size in different studies [55].
                                                             
1 Co-authors: Annalouise O’Connor, Stephen Orena, Karen Corbin, Raad Gharaibeh, Andrew Swick 
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                In response to bacterial, antimicrobial defence molecules (ADMs) are released as endogenous 
antibiotics, which are central to both the innate and adaptive arm of mucosal host defense within the 
gut. β-defensins are one of major classes of ADMs. Recent work showed that β-defensins can bind to the 
melanocortin 4 receptor (MC4R) to control feeding and body weight providing another mechanism 
linking gut microbiome and energy balance [48]. 
                The current obesity epidemic is associated with the change of diet and sedentary lifestyle in 
modern life. A high-fat diet is regarded as a risk factor for obesity as it contributes to a positive energy 
balance and a short-term positive fat balance [71]. In the meantime, it is well established that the 
consumption of different types of fat is associated with different rates of weight gain in obese animals 
[72]. Although there are controversies, it is believed that SFA are more obesigenic than PUFA [73, 74, 
76]. Early studies showed that animals fed with PUFA have lower weight gain than SFA [77]. The 
observed difference in weight gain might be explained by the differences in capacity to control appetite 
or effects on energy expenditure. Human studies demonstrated that PUFA may exert a relatively 
stronger control over appetite than SFA [74]. A diet rich in PUFAs also results in increased energy 
expenditure with preferential stimulation of the thermogenic activity of brown adipose tissue [77] and 
diet-induced thermogenesis (DIT) [72].  
                In addition, PUFA are oxidized more rapidly than SFA, and as a result, decrease serum 
triacylglycerol level and fat accumulation [78, 79]. In rats, the consumption of a PUFA rich (from 
safflower oil) diet results in a higher lipoprotein lipase (LPL) activity in heart and skeletal muscle than 
does a SFA diet. Compared to SFA, PUFA is regarded as the preferred activator of peroxisome 
proliferator-activated receptors delta, gamma and alpha (PPAR-δ, PPAR-γ and PPAR-α). PPAR signaling is 
able to up-regulate the expression of enzymes involved in conversion of fatty acids to acyl-coenzyme A 
esters, fatty acid entry into mitochondria and peroxisomal and mitochondrial fatty acid catabolism [81]. 
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In addition, PUFA selectively decrease sterol regulatory element-binding protein 1 (SREBP-1), which is 
considered to be strongly involved in the transcriptional regulation of lipogenic enzymes [82]. 
                Recent studies also show that dietary fats also affect populations of gut microbes and their 
metabolic end products. A high-fat-fed animal displays a significant shift in both bacterial and 
metagenomic profiles as compared to an animal on a normal, chow diet [83]. Western diet-associated 
cecal microbiota are characterized by a reduction in Bacteroidetes and an increase in Firmicutes [83]. 
Also, it has shown that the composition of the murine gut microbiome was determined by a high-fat diet 
independent of obesity [84]. Hildebrandt et al. found that a high-fat diet was associated with murine gut 
microbiome alterations characterized by a decrease in Bacteroidetes and an increase in both Firmicutes 
and Proteobacteria in the presence and absence of obesity. Thus, gut microbiome provides another 
mechanism that connects dietary fats and obesity. 
                In this study, we tested the effect of modulation of the gut microbiome by antibiotics on energy 
balance in Sprague Dawley rats fed a 45% high fat diet containing primarily saturated fatty acids 
saturated fatty acids (SFA) vs. polyunsaturated fatty acids (PUFA) as the main source of lipids. The rats 
within these two dietary groups were then treated with either an antibiotics or a vehicle to modulate 
the microbiome. We hypothesized that rats fed with a PUFA diet would have less weight gain than those 
fed a SFA diet by less food intake and more energy expenditure due to the modulation of peripheral 
energy balance signaling from the gut, adipose tissue, pancreas to the brain independent of the gut 
microbiome. The difference of weight change would be seen between SFA diet and PUFA diet when gut 
microbiome is modulated by antibiotics
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Methods  
Animals, Diet and Tissue Collection  
                This study was approved by the University of North Carolina Institutional Animal Care and Use 
Committee. 32 Sprague Dawley male rats (aged 7-week, Charles River Laboratories, USA) were 
randomized to one of two diet groups (n=16 per group, phase 1) as follows: 1) SFA-rich diet (45% energy 
from fat, predominant source butter and lard), and; 2) PUFA-rich diet (45% energy from fat, 
predominant source safflower oil rich in n-6 PUFA) (both Research Diets, New Brunskwick, NJ, USA). The 
composition of each diet is indicated in Table 2 and Table 3.  Animals were housed singly for accurate 
measurement of food intake and energy expenditure. Following 36-day of diet intervention, feces were 
collected and stored at -80oC for gut microbiome analysis. Then animals were further randomized to 
either antibiotic treatment (Abx) or control group (n=8/ group, phase 2) as follows: 1) 
Imipenem/cilastatin sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled water), for a 
treatment period of 7 days. Treatment and control were given via water. On the morning following the 
final treatment day, food was removed from the animals at the end of the dark cycle. Feces were 
collected, stored at -80oC for gut microbiome analysis.  Animals were euthanized via exsanguination 
under isoflurane and death confirmed via bilateral pneumothorax. Whole blood was collected via 
cardiac puncture under anesthesia and centrifuged at 3000 RPM for 15 minutes. Serum was collected 
after centrifugation, stored at -80 oC. Small intestine and colon were collected and stored in RNAlater 
(Life Technologies, Carlsbad, CA, USA) at -20 oC. White adipose tissue, brown adipose tissue, liver were 
collected, snap frozen in liquid nitrogen, stored at -80 oC. (see Figure 3 for study design) 
Assessment of body weight, food intake and energy expenditure  
                Body weight and food intake were measured 3 times a week (Monday, Wednesday, Friday 9:00 
am) during phase 1 of the study and measured daily during phase 2 and in real-time over the 24-hour 
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metabolic rate assessment. As much as possible, spillage was accounted for by collecting and measuring 
smaller pellets and crumbs from the cage floor. Metabolic rate was assessed on 2 occasions: on the final 
day of the 36-day diet intervention period and the 7-day diet and antibiotic treatment period. During 
the energy expenditure measurements, animals were housed in individual metabolic cages (TSE systems,  
St Louis, MO, USA) for a period of 24-hours. The difference between the oxygen (O2) and carbon dioxide 
(CO2) concentrations in the cages were compared with a reference environment, and used to calculate 
oxygen consumption volume (VO2), carbon dioxide production volume (VCO2), respiratory exchange 
ratio (RER) and heat production (H). Animals were acclimated to the metabolic cages for at least one day 
prior to the measurement period.   As there were only 8 metabolic cages, 32 animals were divided into 4 
groups to measure energy expenditure (EE) for 4 consecutive days (see Table 4). Each group contained 2 
rats from each treatment (SFA_NonAbx, SFA_Abx, PUFA_NonAbx and PUFA_Abx treatment). As it took 
about 3 hours to calibrate the machine and change animals in acclimated cage and metabolic cage, 21 
hours’ data were collected to calculate the EE.  
Assessment of microbiome  
                Fecal pellets were collected on 2 occasions: on the final day of the 36-day diet intervention 
period and the 7-day diet and antibiotic treatment period. Between-group differences in microbial 
richness and diversity were measured. DNA was extracted from fecal pellets using QIAamp DNA Stool 
Mini Kit (Qiagen, Valencia, CA, USA), according to manufacturer’s protocol.  After the concentration and 
quality were determined with NanoPhotometer (Implen GmbH, Munich, Germany), sequencing of the 
16S, V6 region was performed on Illumina sequencing system by Dr. Mike Wang's lab at David H. 
Murdock Research Institute (DHMRI, Kannapolis, NC, USA). The bacterial and bioinformatic analysis was 
performed by Dr. Raad Gharaibeh (UNCC, NC, USA).  
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Quantitative reverse transcriptase PCR  
                RNA was extracted from the ileum, colon, white adipose tissue using PureLink® RNA Mini Kit 
(Life Technologies, Carlsbad, CA, USA) according to manufacturer’s protocol. After the concentration 
and quality were determined with NanoPhotometer (Implen GmbH, Munich, Germany), quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR) method was used for the assessment of gene 
expression. First, cDNA synthesis was performed using High-Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems, Foster City, CA, USA) on an Eppendorf Mastercycle ProS (Eppendorf, Hamburg, 
Germany). The second part was performed on the LightCycler® 480 Real-Time PCR System (Roche, 
Penzberg, Upper Bavaria, Germany) using LightCycler® 480 Probes Master (Roche, Penzberg, Upper 
Bavaria, Germany). TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) were 
purchased for the following genes: Defb1 (β-defensin 1), Defb2(β-defensin 2), Defb3 (β-defensin 3), 
Defb4 (β-defensin 4), Pyy (PYY), Gcg (GLP-1), Adipoq (adiponectin), Lep (leptin), Pparg (PPARγ), Srebf1 
(SREBP1) and Gapdh (glyceraldehyde 3-phosphate dehydrogenase). The real-time PCR reactions were 
run in triplicate, and data were retrieved as CT values normalized to Gapdh and log2 transformed for 
subsequent statistical analysis. Final data were expressed as ratios between sample, and the average of 
the SFA_NonAbx group for each gene.  
Plasma metabolic hormones and β-defensins assessment 
                Insulin, leptin, GIP, PYY, PP, amylin and ghrelin were analyzed using bead-based multiplex 
assays (Millipore, Billerica, MA) on a Luminex 100 TM (LUminex, Austin, TX). Total β-defenins, β-defensin 
14, adiponectin were measured by enzyme-linked immunosorbent assay ELISA (Millipore or 
MyBioSource, Inc, San Diego, California, USA). Procedures are according to manufacturer’s protocol. 
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Bioinformatics analysis 
                The bioinformatics analysis of gut microbiome was performed by Dr. Raad Gharaibeh (UNCC, 
USA) described as follows.  
                A single Illumina HiSeq2000 sequencing lane was used to generate 74,502,452 paired-end reads, 
100 bases long, for a total of 73 multiplexed samples targeting the V6 region of the 16S rRNA gene. The 
raw reads were subjected to a QC check using FastQC 
(www.bioinformatics.babraham.ac.uk pro ects fast c  ) and then processed as described previously [86, 
87] except that a minimum of 70 continuous matching nucleotides at 97% similarity across the length of 
the ungapped alignment was required to produce each merged sequence. For OTU clustering, we used 
the program AbundantOTU+ v.0.93b (http://omics.informatics.indiana.edu/AbundantOTU/otu+.php) 
with the “-abundantonly” option and reads from the each comparisons group were clustered together, 
i.e. if the comparison was between SFA and PUFA, reads belonging to those samples were clusters alone.  
Sequences that were not clustered into an OTU (singletons) were excluded from further analyses.  We 
employed UCHIME (http://www.drive5.com/uchime/) and the Gold reference database to screen for 
the presence of chimeras in our OUT sequences and chimeric sequences were removed.  
                To facilitate the taxonomic classification and to compensate for the short read length of the 
generated OTUs, BLASTn v. 2.2.26+ was used with an expectation value of e-5 to align the OTU 
sequences to the Silva database (release 108, http://www.arb-silva.de/).  After that, the standalone 
version of the RDP classifier [88] v. 2.5 was used to classify the full-length Silva sequences with the best 
BLASTn match to the OTU se uence re uiring an RDP confidence score ≥ 80%.  A pivot table was 
generated where each row represents a sample and each column contains the raw counts for each OTU.  
Those raw counts were normalized and log transformed according to the following equation:  
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Normalized and log transformed OTU counts were used to produce a Bray-Curtis dissimilarity matrix 
that was fed into mothur [89]  v.1.25.0 for Principle Co-ordinate Analysis (PCoA). 
                To ensure the results are not pipeline-dependent, a parallel analysis using QIIME v.1.7.0 [90] 
was also conducted, utilizing both de novo (at 97% similarity level) and close-reference OTU picking 
approaches (at 97% similarity level using the Greengenes 97% reference dataset, release of May 2013) 
and yielded similar results. 
Statistical analysis 
                All statistical analysis was carried out using SPSS 15.0 software (IBM). All values were expressed 
as mean and standard error of the mean. For body weight and food intake data, results were analyzed 
for equal variances, followed by one-way repeated ANOVA in phase 1 and two-way repeated ANOVA in 
phase 2. In phase 1, energy expenditure data was analyzed by Student’s t-test. In phase 2, gene 
expression data, protein expression data, and energy expenditure data were analyzed by two-way 
ANOVA with equal variance or Friedman test with unequal variance. Tukey or Mann Whitney U was used 
as post hoc analysis. p<0.05 was considered statistically significant. 
Results 
The effect of dietary fat type on body weight, food intake and energy expenditure 
                To determine the effect of different types of high-fat diet with varying saturated and 
polyunsaturated fatty acid content on energy balance, body weight and food intake were analyzed with 
one-way repeated ANOVA. We found a significantly higher (p=0.016) body weight gain on the SFA diet 
compared with the PUFA diet (Figure 4).  Student’s t-test analysis showed that the significant weight 
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difference between groups began at day 10 and continued throughout the diet intervention (p<0.05, 
Figure 4). After 36 days of diet intervention, the body weight of rats fed with the SFA diet was 8.68% 
higher than the PUFA diet (p<0.05, Figure 4). Similarly, we found a significantly higher (p<0.05) food 
intake on the SFA diet compared with the PUFA diet (Figure 5). The total food intake per rat on the SFA 
diet was 9.12% more than on PUFA diet throughout 36 day diet intervention (p<0.05, Figure 6). However, 
when food intake was normalized to body weight (calorie intake per kg body weight of rat), no 
difference between groups was observed (Figure 7).  Energy expenditure was measured at the end of 36 
day diet intervention. No significant difference was seen between groups (Table 5). 
Gut microbiome in response to diet intervention and antibiotic treatment 
                To determine the effect of dietary fatty acids and antibiotic treatment on gut microbiota 
richness and diversity, 16S rRNA of fecal microbiota was analyzed. We found that the 36 day different FA 
diet intervention did not change gut microbiota α-diversity and β-diversity (Figure 8a and Figure 8b). The 
7-day antibiotic treatments changed rat gut microbiota α-diversity (p=0.01) (decreased about 50%) and 
β-diversity on SFA diet (Figure 9a and Figure 9b). The effect of antibiotic treatment on gut microbiota of 
rats on the PUFA diet was smaller than that seen on the SFA diet.  There was a trend that 7-day 
antibiotic treatments decreased the gut microbiota richness 28.6% (p=0.06) and changed the β-diversity 
on the PUFA diet (Figure 9a and Figure 9b).   
Antibiotic treatment on body weight, food intake and energy expenditure 
                During the 7-day antibiotic treatment, daily body weight and food intake were recorded. We 
used two-way repeated ANOVA to see the effect of dietary fat type and antibiotic or their interaction 
with energy balance. We found that rats on the SFA diet were heavier (p=0.04) than those on the PUFA 
diet (Figure 10). However, no significant difference was seen between antibiotic and vehicle treatment 
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on body weight gain during the 7 days (Figure 10). Regarding food intake, we found that antibiotic 
treatment significantly decreased total daily food intake per rat (p=0.006) and daily food intake per kg of 
body weight in rats irrespective of dietary fat types (p<0.001) (Figure 11 and Figure 12). Daily food 
intake per rat and daily food intake per kg of body weight were significantly lower with antibiotic 
treatment than vehicle on Day 1, Day 2, Day 3 and Day 5 (p<0.05, Figure 11 and p<0.01, Figure 12). 
However, there is no significant difference between SFA diet and PUFA diet on daily food intake per rat 
and food intake per kg of body weight during the 7 day of antibiotic or vehicle treatment (Figure 11 and 
Figure 12). Energy expenditure was measured at the end of the 7 day antibiotic or vehicle treatment 
(Table 6). No significant differences were seen among the treatments.  
Gut β-defensins gene expression and serum protein expressions in response to dietary fat 
types and antibiotic treatment 
                To investigate whether the expression of gut β-defensins changed in response to different 
dietary fat types and antibiotic treatment, qPCR was used to measure gene expression of β-defensin-1, 
β-defensin-2, β-defensin-3, β-defensin-4 , and β-defensin-14 in ileum and colon which are the major 
colonization sites of gut microbiota. The gene expression of β-defensin-1 and β-defensin-14 was not 
detected in ileum and colon or the gene expression is too low to be detected by the machine (data not 
shown). The gene expression of β-defensin-2, β-defensin-3, β-defensin-4 were detectable but at very 
low levels. Rats on the PUFA diet increased β-defensin-2 (p=0.009), and β-defensin-3 gene expression 
(p=0.012) in ileum compared of rats on the SFA diet with and without antibiotic treatment (Figure 13). 
No significant differences between antibiotic and vehicle treatment were seen in β-defensins gene 
expression in both ileum and colon (Figure 13 and Figure 14). As it was found β-defensins are the new 
potential ligands to MC4R in brain, which might enter into blood and pass through blood brain barrier, 
serum total β-defensins and β-defensin 14 protein expression were measured by ELISA. No significant 
differences were noted due to diet or antibiotics (Figure 15 and Figure 16).  
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Gut hormone PYY and GLP-1 gene expression in response to dietary fat types and antibiotic 
treatment 
                PYY and GLP-1 are secreted by L cells which are classically thought to be located in the distal 
gut, predominantly the ileum and colon. Therefore, we investigated PYY (Pyy) and GLP-1 (Gcg) gene 
expression in ileum and colon by qPCR. We found that rats on the SFA diet increased ileum Pyy (p=0.041) 
and colon Gcg (p=0.036) compared of rats on the PUFA diet with and without antibiotic treatment 
(Figure 17). No significant differences were seen in PYY and GLP-1 gene expression between antibiotic 
and vehicle treatment in ileum and colon (Figure 17). 
White adipose tissue leptin, adiponectin, PPARγ, and SREBP1 gene expression in response to 
dietary fat types and antibiotic treatment 
                Gene expression of leptin, adiponectin, PPARγ and SREBP1 in white adipose tissue (WAT) were 
determined by qPCR. We found that rats on the PUFA diet increased adiponectin (p=0.019) and 
decreased SREBP1 (p=0.010) gene expression in WAT with and without antibiotic treatment (Figure 18). 
Also, two way ANOVA analyses showed that there is an interaction between dietary fats and antibiotics 
treatment on leptin (p=0.029), adiponectin (p=0.027) and PPARγ (p=0.013) gene expression (Figure 18).  
Serum peripheral energy balance signals in response to dietary fat types and antibiotics treatment 
                We measured serum ghrelin, pancreatic polypeptide, PYY, insulin, glucagon, leptin and 
adiponectin. No significant differences were seen among different treatments (Figure 19-Figure 26).  
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Discussion 
 
                Not only the quantity of ingested fats, but also the composition the fatty acids have an effect 
on obesity development. The results from our study supported the hypothesis that SFA diet is more 
obesogenic than PUFA diet due to the increased food intake. However, we failed to observe an 
association between dietary FA and gut microbiota on energy balance as the knockdown of gut 
microbiota decreased rats’ food intake regardless of different dietary FA.  
                This study failed to find the potential mechanism for rats to increase food intake as no 
differences were seen in serum protein expression of ghrelin, pancreatic polypeptide, PYY, insulin, 
glucagon, leptin and adiponectin. However, the secretion and circulating levels of these 
peripheral signals are all influenced by recent energy intake and dietary macronutrient content as well 
as were time-dependent after a single meal [91, 92], it may be necessary to investigate these peripheral 
hormone levels at different time points after a meal during the study to get the true whole picture of 
peripheral signals in response to different dietary fat types. This is a limitation of our study to be 
improved in future.  
                In this study, there was no effect of dietary fat types on energy expenditure. Total energy 
expenditure was measured including obligatory energy expenditure which is required for performance 
of cellular and organ functions (also called as resting energy expenditure), physical activity and adaptive 
thermogenesis providing a comprehensive picture of the physiological effect of dietary fatty acid 
composition on energy expenditure.  Thus, data suggests that there is no significant difference between 
SFA diet and PUFA diet on long term total energy expenditure. 
                36-day diet intervention did not change gut microbiota α-diversity and β-diversity. However, 
we cannot exclude the possible effect of dietary fatty acids on compositional pattern of gut microbiota. 
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It was reported that lard-based high fat diet increased the the abundance of the Mollicutes class of the 
Firmicutes phylum and reduced the abundance of Bacteroidetes.[83]  But little has been reported on 
effects of different fatty acid diet on gut microbiota compositional pattern, which remains to be clarified 
in a future study. 
                Here in, qPCR analysis showed that PUFA diet increased ileum β-defensin 2 and β-defensin 3 
gene expression with and without antibiotic treatment. Β-defensins are components of endogenous 
antimicrobials which provide a first of line of defence against potentially pathogenic microbes at the 
body’s mucosal frontiers [46]. However, as the secretion of β-defensins is also in response to bacteria in 
the intestine, the real relationship between β-defensins, dietary fatty acids and gut microbiota remains 
to be clarified in a future study.  
                A 7-day imipenem/cilastatin treatment successfully decreased gut microbiota. Interestingly, the 
effect of antibiotics treatment on gut microbiota of rats with the PUFA diet was smaller than those on 
the SFA diet.  The 7-day antibiotic treatment significantly decreased rats’ gut microbiota richness about 
50% on the SFA diet but only decreased 28.6% on the PUFA diet. The result indicated that PUFA diet 
might protect gut microbiota from antibiotics due to the proinflammatory property of n-6 PUFA as our 
PUFA diet was safflower oil based high fat diet which was composed mainly of n-6 PUFA.  
                The blunting of gut microbiota significantly decreased the food intake regardless of different 
dietary fatty acids. Thus, based on this result, no association was evident between dietary fatty acids on 
food intake.  
                To discover potential mechanisms linking gut microbiota and food intake, we examined 
potential mediators. However, no differences between antibiotic and vehicle treatment were seen in 
serum protein expression of ghrelin, pancreatic polypeptide, PYY, insulin, glucagon, leptin and 
adiponectin. As previously discussed, only one study time point might not reflect the dynamics of these 
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peripheral hormones in response to gut microbiota change.  Thus, how gut microbiota influenced food 
intake remains to be clarified in a future study.  
                Recent work showed that β-defensins can bind to the MC4R to control feeding and body weight 
[48]. Intracerebroventricular injection of human β-defensin 3 (HBD3) to male Wistar rats has an 
inhibitory effect on both the food intake and body weight gain with the potential mechanism of blocking 
AgRP [49]. Thus, we measured serum total β-defensins level and β-defensin 14 (homologues of HBD3) 
[93]. No differences were seen between PUFA diet and SFA diet or between antibiotic and vehicle 
treatment. Thus, β-defensins were not involved in mediating the different effects of SFA and PUFA diet 
or gut microbiota effects on energy balance regulation. 
                In summary, SFA are more obesogenic than PUFA due to increased food intake. Decreased gut 
microbiota decreased rats’ food intake regardless of dietary fatty acid composition.  There is no 
association between dietary fat types and gut microbiome on energy balance. The potential mechanisms 
for how rats gained more weight with increased food intake and how the ablation of gut micrflora by 
antibiotics resulted in decreased food intake remain to be clarified in a future study.
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Figure 3 Study Design  
32 7-week-old Sprague Dawley male rats were randomized to one of two diet groups (n=16 per 
group) as follows: 1) SFA-rich diet (45% energy from fat, predominant source butter and lard), 
and; 2) PUFA-rich diet (45% energy from fat, predominant source safflower oil). Animals were 
housed singly for accurate measurement of food intake and energy expenditure.  Body weight 
and food intake were measured 3 times a week. Following 36-day of diet intervention, feces 
were collected and energy expenditure was measured. Then animals were further randomized 
to either antibiotic treatment or control group (n=8/ group) as follows: 1) Imipenem/cilastatin 
sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled water), for a treatment 
period of 7 days. Treatment and placebo were given via water. On the final day of 7-day 
antibiotic or vehicle treatment, feces were collected and energy expenditure was measured.  
Animals were euthanized via exsanguination under isoflurane and death confirmed via bilateral 
pneumothorax. Whole blood, white adipose tissue, brown adipose tissue, and liver were 
collected for further analysis.  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; Abx, Antibiotics; EE: 
energy expenditure; +, with; -, without
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Figure 4 The effect of diet intervention on body weight:  
During phase 1 of the study, 32 7-week-old Sprague Dawley male rats were randomized to two 
diet groups: SFA diet group (n=16) and PUFA diet group (n=16). Rats’ body weight was measured 
3 times a week. Mean ± SEM is shown. One-way repeated ANOVA was used. Rats treated with 
SFA diet gained more body weight compared with those with PUFA diet (p=0.016). *T-test was 
used. The weight of rats treated with SFA diet is significantly higher than those with PUFA diet 
from D10 to D36 (p<0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids.
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Figure 5 The effect of diet intervention on food intake:  
During phase 1 of the study, 32 7-week-old Sprague Dawley male rats were randomized to two 
diet groups: SFA diet group (n=16) and PUFA diet group (n=16). Rats’ food intake was measured 
3 times a week. Mean ± SEM is shown. One-way repeated ANOVA was used. Rats treated with 
SFA diet took in more food than those with PUFA diet. (P<0.05) 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids.
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Figure 6 The effect of diet intervention on total food intake for 36 days:  
During phase 1 of the study, 32 7-week-old Sprague Dawley male rats were randomized to two 
diet groups: SFA diet group (n=16) and PUFA diet group (n=16). 36 days’ of food intake was 
added up. Mean ± SEM is shown. Student’s t test was used. Rats treated with SFA diet took in 
more food than those with PUFA diet (*P<0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids. 
 
   
Figure 7 Effect of diet intervention on food intake normalized to body weight 
During phase 1 of the study, 32 7-week-old Sprague Dawley male rats were randomized to two 
diet groups: SFA diet group (n=16) and PUFA diet group (n=16). Rats’ food intake and body 
weight were measured 3 times a week.  Rats’ food intake was normalized to their body weight. 
Mean ± SEM is shown. One-way repeated ANOVA was used. No significant differences were 
seen.  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids. 
34 
 
     
 
Figure 8 Effect of diet intervention on gut microbiome richness (α-diversity) and β-diversity 
32 7-week-old Sprague Dawley male rats were randomized to two diet groups: SFA diet group 
(n=16) and PUFA diet group (n=16) for 36 days.  At the end of 36 day diet intervention, rats’ 
feces were collected. DNA was extracted from feces. Sequencing of the 16S, V6 region was 
performed on Illumina sequencing system to determine the effect of difference diet on gut 
microbiome richness (α-diversity) and β-diversity. Figure 8a: Mann-Whitney U test was used to 
compare α-diversity between groups. Figure 8b: PCoA was used to compare β-diversity betw 
een groups. No significant differences were seen. 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids. 
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Figure 9 Effect of different diet intervention ± antibiotic treatment on rats’ gut microbiome 
richness (α-diversity) and β-diversity 
32 7-week-old Sprague Dawley male rats were randomized to two diet groups: SFA diet group 
(n=16) and PUFA diet group (n=16) for 36 days.  At the end of 36-day diet intervention, animals 
were further randomized to either antibiotic treatment or control group (n=8/ group) as follows: 
1) Imipenem/cilastatin sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled 
water), for a treatment period of 7 days. At the end of 7 day antibiotic or vehicle treatment, rats’ 
feces were collected. DNA was extracted from feces. Sequencing of the 16S, V6 region was 
performed on Illumina sequencing system to determine the effect of antibiotic treatment on 
rats’ gut microbiome richness (α-diversity) and β-diversity on the SFA diet or the PUFA diet. 
Figure 9a: Mann-Whitney U test was used to compare α-diversity between groups. Figure 9b: 
PCoA was used to compare β-diversity between groups. Antibiotic treatment decreased α-
diversity compared with vehicle treatment (p=0.01 on the SFA diet and p=0.06 on the PUFA diet).   
Abbreviation: SFA Abx, saturated fatty acids diet with antibiotic treatment; SFA noAbx, 
saturated fatty acids diet without antibiotic treatment; PUFA Abx, polyunsaturated fatty acids 
diet with antibiotic treatment; PUFA noAbx, polyunsaturated fatty acids diet without antibiotic 
treatment. 
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Figure 10 Effect of different diet intervention ± antibiotic treatment on rats’ body weight   
32 7-week-old Sprague Dawley male rats were randomized to two diet groups: SFA diet group 
(n=16) and PUFA diet group (n=16) for 36 days.  At the end of 36-day diet intervention, animals 
were further randomized to either antibiotic treatment or control group (n=8/ group) as follows: 
1) Imipenem/cilastatin sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled 
water), for a treatment period of 7 days. Daily body weight was measured. Mean ± SEM is 
shown. Two-way repeated ANOVA was used. Rats on SFA-rich diet had higher body weight than 
those on the PUFA (p=0.006). No significant differences were seen between antibiotics and 
vehicle treatment on body weight during 7 days. 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics.
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Figure 11 Effect of different diet intervention ± antibiotic treatment on rats’ food intake   
32 7-week-old Sprague Dawley male rats were randomized to two diet groups: SFA diet group 
(n=16) and PUFA diet group (n=16) for 36 days.  At the end of 36-day diet intervention, animals 
were further randomized to either antibiotic treatment or control group (n=8/ group) as follows: 
1) Imipenem/cilastatin sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled 
water), for a treatment period of 7 days. Daily food intake was measured. Mean ± SEM is shown. 
Two-way repeated ANOVA was used. Antibiotic treatment had an effect on rats’ food intake 
independently (P=0.006). There is no significant difference between SFA-rich diet and PUFA-rich 
diet on daily energy intake during the 7 days. *Antibiotic treatment significantly decreased daily 
food intake on D1, D2, D3, D5 irrespective of fat types (P<0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics.
38 
 
 
 
Figure 12 Effect of different diet intervention ± antibiotic treatment on rats’ food intake 
normalized to body weight 
 32 7-week-old Sprague Dawley male rats were randomized to two diet groups: SFA diet group 
(n=16) and PUFA diet group (n=16) for 36 days.  At the end of 36-day diet intervention, animals 
were further randomized to either antibiotic treatment or control group (n=8/ group) as follows: 
1) Imipenem/cilastatin sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled 
water), for a treatment period of 7 days. Daily rats’ body weight and food intake were measured. 
Food intake was normalized to body weight. Mean ± SEM is shown. Two-way repeated ANOVA 
was used. Antibiotics or vehicle had an effect on rats’  food intake normalized to body weight 
(p=0.000). No significant differences were seen between SFA diet and PUFA diet during the 7 
days. *Antibiotic treatment significantly decreased food intake normalized to body weight on D1, 
D2, D3, D5 irrespective of fat types (P<0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics.
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Figure 13 Effect of different diet intervention ± antibiotic treatment on ileum β-defensin-2 (a), β-
defensin-3 (b) and β-defensin-4 (c) gene expression  
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and tissues were 
collected. RNA was extracted from the ileum. qPCR was used to assess β-defensins gene 
expression. Data were retrieved as CT values normalized to Gapdh and log2 transformed for 
subsequent statistical analysis. Final data were expressed as ratios between sample, and the 
average of the SFA_NonAbx group for each gene. Mean ± SEM is shown. Friedman test was used 
to compare ileum Defb2 expression among groups. Two-way ANOVA was used to compare 
ileum Defb3 and ileum Defb4 expression among groups. PUFA diet increased ileum Defb2 
(p=0.009) and Defb3 (p=0.012) gene expression compared with SFA diet with and without 
antibiotic treatment. No significant differences were seen in ileum Defb2, Defb3, Defb4 gene 
expression between antibiotics and vehicle treatment (P>0.05). Tukey was used as post hoc 
analysis. #p<0.05 compared to SFA_Abx group. 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics, 
Defb, β-defensin. 
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Figure 14 Effect of different diet intervention ± antibiotic treatment on colonβ-defensin-2 (a), β-
defensin-3 (b) and β-defensin-4 (c) gene expression  
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and tissues were 
collected. RNA was extracted from the ileum. qPCR was used to assess β-defensins gene 
expression. Data were retrieved as CT values normalized to Gapdh and log2 transformed for 
subsequent statistical analysis. Final data were expressed as ratios between sample, and the 
average of the SFA_NonAbx group for each gene. Mean ± SEM is shown. Two-way ANOVA was 
used. No significant differences were seen due to diet intervention or antibiotic treatment.  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics, 
Defb, β-defensin.
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Figure 15 Effect of different diet intervention ± antibiotic treatment on serum total β-defensins 
protein expression 
 At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected.  ELISA was used to measure serum total β-defensins protein expression. Mean ± SEM 
is shown. Two-way ANOVA was used. No differences were seen due to diet intervention or 
antibiotic treatment. 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics. 
 
  
Figure 16 Effect of different diet intervention ± antibiotic treatment on serum β-defensin 14 
protein expression  
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. ELISA was used to measure serum β-defensin 14 protein expression. Mean ± SEM is 
shown. Friedman test was used. No differences were seen due to diet intervention or antibiotic 
treatment. 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics. 
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Figure 17 Effect of diet intervention ± Abx on ileum PYY (a), ileum GLP-1 (b), colon PYY (c) and 
colon GLP-1 (d) gene expression  
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and tissues were 
collected.  RNA was extracted from the ileum and colon. qPCR was used to assess gut hormone 
PYY and GLP-1 gene expression. Data were retrieved as CT values normalized to Gapdh and log2 
transformed for subsequent statistical analysis. Final data were expressed as ratios between 
sample, and the average of the SFA_NonAbx group for each gene. Friedman test was used to 
compare ileum Pyy and Gcg gene expression among groups. Two-way ANOVA was used to 
compare colon PYY and Gcg gene expression among groups. SFA diet increased ileum PYY 
(p=0.041) and colon GLP-1 (p=0.036) gene expression compared to PUFA diet with and without 
antibiotic treatment. No significant differences were seen in PYY and GLP-1 gene expression due 
to antibiotic treatment in both ileum and colon tissues (p>0.05). Tukey was used as post hoc 
analysis. # p<0.05 compared to SFA_Abx group. 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics, Pyy, 
gene name for peptide YY (PYY); Gcg, gene name for glucagon-like peptide-1 (GLP-1). 
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Figure 18 Effect of diet intervention ± Abx on leptin (a), adiponectin (b), PPARγ (c) and SREBP1 (d) 
gene expression  
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and tissues were 
collected.  RNA was extracted from the white adipose tissue. qPCR was used to assess white 
adipose tissue Lep (leptin),  Adipoq (adiponectin), Pparg (PPARγ) and Srebf1 (SREBP1) gene 
expression. Data were retrieved as CT values normalized to Gapdh and log2 transformed for 
subsequent statistical analysis. Final data were expressed as ratios between sample, and the 
average of the SFA_NonAbx group for each gene. Mean ± SEM is shown. Two-way ANOVA was 
used. SFA diet decreased adiponectin (p=0.019) and increased SREBP1 (0.010) gene expression 
compared to PUFA diet with and without antibiotic treatment. Diet intervention and antibiotics 
treatment had an interaction on leptin (p=0.029), adiponectin (p=0.027) and PPARγ (p=0.013) 
gene expression.  No significant differences were seen on WAT leptin, adiponectin, PPARγ and 
SREBP1c gene expression due to antibiotic treatment (P>0.05). Tukey was used as post hoc 
analysis. * p<0.05 compared to SFA_NonAbx group, # p<0.05 compared to SFA_Abx group, a 
p<0.05 compared to PUFA_NonAbx group. 
Abbreviation: WAT, white adipose tissue; SFA, saturated fatty acids; PUFA, polyunsaturated fatty 
acids, Abx, antibiotics; Lep, gene name for leptin; Adipoq, gene name for adiponectin; Pparg, 
gene name for PPARγ; Srebf1, gene name for SREBP1 
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Figure 19 Effect of diet intervention ± Abx on serum ghrelin expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. Ghrelin was analyzed using bead-based multiplex assay. Mean ± SEM is shown. 
Friedman test was used. No significant differences were seen in there serum peripheral energy 
balance signals protein expression due to diet intervention and antibiotic treatment (p>0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics 
 
  
Figure 20 Effect of diet intervention ± Abx on serum GIP expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. GIP was analyzed using bead-based multiplex assay. Mean ± SEM is shown. Two way 
ANOVA was used. No significant differences were seen in there serum peripheral energy balance 
signals protein expression due to diet intervention and antibiotic treatment (p>0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics; GIP, 
glucose-dependent insulinotropic polypeptide 
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Figure 21 Effect of diet intervention ± Abx on serum glucagon expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. Glucagon was analyzed using bead-based multiplex assay. Mean ± SEM is shown. Two 
way ANOVA was used. No significant differences were seen in there serum peripheral energy 
balance signals protein expression due to diet intervention and antibiotic treatment (p>0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics 
 
 
Figure 22 Effect of diet intervention ± Abx on serum insulin expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. Insulin was analyzed using bead-based multiplex assay. Mean ± SEM is shown. Two 
way ANOVA was used. No significant differences were seen in there serum peripheral energy 
balance signals protein expression due to diet intervention and antibiotic treatment (p>0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics 
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Figure 23 Effect of diet intervention ± Abx on serum leptin expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. Leptin was analyzed using bead-based multiplex assay. Mean ± SEM is shown. Two 
way ANOVA was used. No significant differences were seen in there serum peripheral energy 
balance signals protein expression due to diet intervention and antibiotic treatment (p>0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics 
 
  
Figure 24 Effect of diet intervention ± Abx on serum adiponectin expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. Adiponectin was measured by ELISA. Mean ± SEM is shown. Two way ANOVA was 
used. No significant differences were seen in there serum peripheral energy balance signals 
protein expression due to diet intervention and antibiotic treatment (p>0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics 
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Figure 25  Effect of diet intervention ± Abx on serum PYY expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. PYY was analyzed using bead-based multiplex assay. Mean ± SEM is shown. Two way 
ANOVA was used. No significant differences were seen in there serum peripheral energy balance 
signals protein expression due to diet intervention and antibiotic treatment (p>0.05).  
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics; PYY, 
peptide YY 
 
Figure 26 Effect of diet intervention ± Abx on serum PP expression 
At the end of 7-day antibiotic or vehicle treatment, rats were euthanized and blood was 
collected. Mean ± SEM is shown. Friedman test was used. PP was analyzed using bead-based 
multiplex assay. Mean ± SEM is shown. Two way ANOVA was used. No significant differences 
were seen in there serum peripheral energy balance signals protein expression due to diet 
intervention and antibiotic treatment (p>0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids, Abx, antibiotics; GIP, 
glucose-dependent insulinotropic polypeptide; PYY, peptide YY; PP, pancreatic polypeptide 
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Table 2: Macronutrients Composition of the SFA and PUFA Diets 
Diets SFA diet PUFA diet 
% gm  kcal gm kcal 
Protein 24 20 24 20 
Carbohydrate 41 35 41 35 
Fat 24 45 24 45 
Total  100  100 
Kcal/gm 4.7  4.7  
 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids 
Table 3: Detailed nutrients ingredients of SFA and PUFA diets 
Ingredient gm  kcal gm kcal 
Casein  200 800 200 800 
L-Cystine 3 12 3 12 
Corn Starch 72.8 291 72.8 291 
Maltodextrin 10 100 400 100 400 
Surcrose 172.8 691 172.8 691 
Cellulose, BW 
200 
50 0 50 0 
Soybean oil 25 225 25 225 
Safflower Oil 0 0 177.5 1598 
Butter 88.75 799 0 0 
Lard 88.75 799 0 0 
Mineral Mix S 
10025 
10 0 10 0 
DiCalcium 
Phosphate 
13 0 13 0 
Calcium 
Carbonate 
5.5 0 5.5 0 
Potassium 
Citrate, 1 H2O 
16.5 0 16.5 0 
Vitamin Mix 
V10001 
10 40 10 40 
Choline 
Bitartrate 
2 0 2 0 
Total 858.15 4057 858.15 4057 
 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids 
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Table 4 Energy Expenditure Measurement Flowchart 
 Acclimated cage Metabolic cage 
Prior to D1 Group 1 No animals 
D1 EE measurement Group 2 Group 1 
D2 EE measurement Group 3 Group 2 
D3 EE measurement Group 4 Group 3 
D4 EE measurement No animals Group 4 
 
Prior to the first day of energy expenditure measurement, Rats in Group 1 entered into 
acclimated cage. On the first day, rats in Group 1 were moved out from acclimated cage and 
entered into metabolic cage, and rats in Group 2 entered into acclimated cage. On the second, 
rats in Group 1 were moved out from metabolic cage. Rats in Group 2 were moved out from 
acclimated cage and entered into metabolic cage. Rats in Group 3 entered into acclimated cage. 
On the third day, rats in Group 3 were moved out from metabolic cage. Rats in Group 3 were 
moved out from acclimated cage and entered into metabolic cage. Rats in Group 4 entered into 
acclimated cage. On the final day, rats in Group 4 were moved out from acclimated cage and 
entered into metabolic cage. 
Abbreviation: EE, energy expenditure. 
Table 5 Effect of Diet Intervention on Energy Expenditure (Mean ± SEM) 
 SFA group PUFA group 
VO2/BW(ml/h/kg) 2298.16±40.88 2371.99±60.14 
VCO2/BW(ml/h/kg) 1660.84±29.37 1720.025±43.68 
RER 0.72±0.0046 0.72±0.0072 
H(kcal/h/kg) 10.89±0.19 11.25±0.28 
 
During phase 1 of the study, 32 7-week-old Sprague Dawley male rats were randomized to two 
diet groups: SFA diet group (n=16) and PUFA diet group (n=16). After 36-day diet intervention, 
rats’ energy expenditure was measured by metabolic cage for 24 hours. The difference between 
the oxygen and carbon dioxide concentrations in the cages were compared with a reference 
environment, and used to calculate oxygen consumption volume, carbon dioxide production 
volume, respiratory exchange ratio and heat. 21 hours’ data was collected. Mean ± SEM is 
shown. Student’s t test was used. No significant differences were seen in energy expenditure 
due to diet intervention (p>0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; BW, body weight; 
VO2, oxygen consumption volume; VCO2, carbon dioxide production volume; RER, respiratory 
exchange ratio; H, heat production
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Table 6 Effect of Diet Intervention ± Abx on Energy Expenditure (Mean±SEM) 
 SFA_NonAbx SFA_Abx PUFA_NonAbx PUFA_Abx 
VO2/BW 
(ml/h/kg) 
2176.76 ± 31.34 2144.91 ± 46.58 
 
2269.80 ± 55.31 
 
2224.70 ± 48.44 
 
VCO2/BW 
(ml/h/kg) 
1548.16 ± 23.15 
 
1503.36 ± 29.21 
 
1602.26 ± 37.62 
 
1545.88 ± 42.61 
 
RER 0.71 ± 0.0080 
 
0.70 ± 0.0045 
 
0.70 ± 0.0051 
 
0.69 ± 0.0051 
 
H 
(kcal/h/kg) 
10.29 ± 0.14 
 
10.12 ± 0.21 
 
10.72 ± 0.26 
 
10.48 ± 0.24 
 
 
32 7-week-old Sprague Dawley male rats were randomized to two diet groups: SFA diet group 
(n=16) and PUFA diet group (n=16). At the end of 36-day diet intervention, animals were further 
randomized to either antibiotic treatment or control group (n=8/ group) as follows: 1) 
Imipenem/cilastatin sodium at 50 mg/kg of body weight/day, or; 2) vehicle control (distilled 
water), for a treatment period of 7 days. At the end of 7 day antibiotic or vehicle treatment, rats’ 
energy expenditure was measured by metabolic cage for 24 hours. The difference between the 
oxygen and carbon dioxide concentrations in the cages were compared with a reference 
environment, and used to calculate oxygen consumption volume, carbon dioxide production 
volume, respiratory exchange ratio and heat. 21 hours’ data was collected. Mean ± SEM is 
shown. Two way ANOVA was used. No significants differences were seen in energy expenditure 
due to diet intervention or antibiotic treatment (p>0.05). 
Abbreviation: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; Abx, antibiotics; BW, 
body weight; VO2, oxygen consumption volume; VCO2, carbon dioxide production volume; RER, 
respiratory exchange ratio; H, heat production 
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CHAPTER 3: DISCUSSION 
 
                Not only the quantity of ingested fats, but also the composition the fatty acids have an effect 
on obesity development. In both human and animal studies, it showed that SFA are more obesigenic 
than are PUFA due to their different effects on appetite control, energy expenditure, and oxidation rate. 
Recent work also has identified a role for gut microbiota in the onset of obesity. In addition, a high-fat-
fed animal displays a significant shift in both bacterial and metagenomic profiles as compared to an 
animal on a normal, chow diet [83]. However, a direct connection between a specific type of fats and 
gut microbes contributing to obesity should be further investigated.   
                In this study, we were interested in the effect of modulation of gut microbiome by antibiotics 
on food intake and energy expenditure in Sprague Dawley rats treated with 45% high fat diet containing 
different dietary fat types. We confirmed that SFA are more obesogenic than PUFA with increased food 
intake. However, no association between dietary fat types and gut microbiome was observed on energy 
balance. In this chapter, we would discuss the pertinent and research questions, as well as the 
limitations in the field of study.  
The effect of different dietary fat types on body weight, food intake and energy 
expenditure 
 
                Recent evidence suggests that the overall amount of fat intake is not the only factor 
determining weight gain and fat store. Fat quality is important as well [72, 73, 76]. In this study, we 
investigated the effect of a high fat diet (45% calorie from fat) containing different fatty acids on rats’ 
body weight, food intake and energy expenditure. The SFA diet is lard and butter based high fat diet
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which is main source of dietary SFA in human diet. The PUFA diet is safflower oil based diet which is 
mainly composed of n-6 PUFA. Therefore, our study was to compare SFA with n-6 PUFA on the whole 
body energy balance modulation.   
                We found that rats on the SFA diet had a significantly higher weight gain than did those on the 
PUFA diet starting from Day 10 to the end of the study (Figure 4). This result is accordance with others’ 
reported results [94]. The daily food intake of rats on the SFA diet was higher than in those on the PUFA 
diet during the 36-day diet intervention (Figure 5). No significant differences were seen in energy 
expenditure due to different diet intervention (Table 5). Based on these results, we conclude that the 
rats on the SFA diet had a higher weight gain mainly due to the increased food intake compared with 
those on the PUFA diet. 
                However, it is interesting that when food intake was normalized to rats’ body weight, no 
significant differences were seen between the two groups, although during the first 10 days, there was a 
slight increase in food intake per kg body weight for rats on the SFA diet (Figure 7). Body weight is an 
important determinant of energy requirement as energy requirement is defined by the amount of food 
energy needed to balance energy expenditure in order to maintain body size, body composition and a 
level of necessary and desirable physical activity consistent with long-term good health. Based on the 
result that there were no differences on food intake per kg body weight between the two groups, we 
speculate that there is no food preference of rats between the SFA diet and the PUFA diet. The SFA diet 
didn’t cause rats’ overeating during the 36-day diet intervention.  
                If the rats took in the food amount according to the body weight (that is to say, their energy 
requirement), then the reasons that the SFA diet caused rats to gain more weight than did the PUFA diet 
might be due to the following two assumptions. 
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                First, we still can see that during the first 10 days of diet intervention, there was a slight 
increase in food intake per body weight (Figure 7). It might be that the first 10 days’ overeating 
determined the rats treated with the SFA diet gained more weight than those on the PUFA diet. This 
assumption can be confirmed that rats treated with SFA diet were significantly heavier than those with 
PUFA diet starting at day 10 (Figure 4). Second, energy absorption efficiency might be different between 
the SFA diet and the PUFA diet. In fact, fatty-acid chain length and number of double bonds can 
influence fat absorption [95]. SFA might have higher absorption efficiency than PUFA. However, on the 
contrary to our assumption, Nicole de Wit et al showed that compared with the diet rich in SFA, the net 
energy absorption was higher for PUFA-rich diet in their study.[94]  
                Therefore, we speculate the first 10 days after starting high fat diet containing different fatty 
acids is the key period causing the weight difference between the two groups.   
                Our study results showed no effect of dietary fat types on energy expenditure (Table 5). 
However, Mercer et al showed in their study that compared with a diet rich in SFA, a diet rich in PUFA 
results in increased energy expenditure with preferential stimulation of the thermogenic activity of 
brown adipose tissue [77]. We must point out here that although PUFA has more potential to stimulate 
brown adipose tissue, mice fed with the PUFA diet had less brown adipose tissue than did those fed with 
the SFA diet in their study [77]. That is to say, the total capacity to stimulate energy expenditure by 
brown adipose tissue might be equal between a SFA diet and a PUFA diet. Our results did not contradict 
their findings.  
                Casas-Agustench et al proposed that a PUFA diet increases energy expenditure due to that a 
higher diet-induced thermogenesis (DIT) than caused by a SFA diet [72]. In fact, in their study, diet 
induced thermogenesis reflected an acute effect of dietary fatty acids on energy expenditure 5 hours’ 
after the meal [72]. In our studies, we measured total energy expenditure including obligatory energy 
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expenditure which is required for performance of cellular and organ functions (also called as resting 
energy expenditure), physical activity and adaptive thermogenesis [96] after a 36-day diet intervention. 
This involves a long term metabolic adaptation to dietary fatty acids, providing a more comprehensive 
picture of the physiological effect of dietary fatty acid composition on energy expenditure. Actually, our 
results for energy expenditure are supported by Wongsuthavas et al as they also proved no enhanced 
energy expenditure on a PUFA diet compared with a SFA diet in in broiler chickens [97].  
Peripheral signals of energy balance in response to dietary fat type 
                Hunger and satiety endocrine hormones play a vital role in controlling energy balance as they 
act in many different sensing and signaling pathways. While chain length of a dietary fatty acid has been 
shown to have a significant effect on satiety hormone release [98, 99], less is known about the hormonal 
responses based on the degree of saturation in fatty acids. In this study, we investigated PYY, GLP-1 
gene expression in intestine and leptin, adiponectin gene expression in white adipose tissue.  
                We found that compared with the PUFA diet, the SFA diet increased ileum PYY and colon GLP-1 
gene expression (Figure 17). PYY and GLP-1 are often considered as co-stored or co-released by L cells in 
distal gut [41]. L-cells exhibit a polarized morphology with an apical surface contacting the gut lumen 
and a basolateral membrane in close proximity to the circulatory system. This so-called “open-type” 
morphology should enable them to sense dietary nutrients and non-nutrient substances, present in the 
intestinal lumen [100]. As lipid reaches the distal portion of the gut, GLP-1 and PYY are secreted in 
response to increasing lipid calories [101, 102]. The gene expression PYY and GLP-1 was consistent with 
the food intake as we found that rats fed with the SFA diet increased food intake compared with the 
PUFA diet (Figure 5).   
                Our results also showed that compared with the SFA diet, the gene expression of WAT 
adiponectin was increased in rats on the PUFA diet with and without antibiotic treatment (Figure 18). 
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The secretion of adiponectin is negatively related to body adipocytes as circulating adiponectin 
concentrations are reduced in obese animals [103] and humans [104]. The physiological effect of 
adiponectin on food intake and energy expenditure is controversial. It is found that adiponectin could 
increases hypothalamic AMPK phosphorylation to stimulate food intake and suppress energy 
expenditure by binding to adiponectin receptors in hypothalamus [26]. Interestingly, it is also found that 
intracerebroventricular administration of adiponectin decreased body weight with increasing energy 
expenditure suggesting a negative regulating pathway for adiponectin effect on energy balance [27].  
                Treatment with PPARγ agonists resulted in increased adiponectin levels [105]. Fatty acids 
from the n−6 and n−3 families of fatty acids and their respective eicosanoid products are the physiologic 
ligands for PPARγ [106]. We measured PPARγ gene expression in WAT and found no difference in 
gene expression between the two diets (Figure 18). We speculate that the PUFA diet up regulated 
adiponectin gene expression independent from PPARγ.  
                SREBP1 positively regulates adiponectin gene transcription in vitro [107]. In our results, we 
found that compared with the SFA diet, the PUFA diet decreased Srebf1 expression with and without 
antibiotic treatment (Figure 18). This result is consistent with previous findings [108]. Based on our 
results, we can’t speculate on any relationship between SREBP1 and adiponectin in vivo. In fact, 
physiological effect between SREBP1 and adiponectin is opposite. Overexpression of SREBP1c in white 
adipose tissue is associated with insulin resistance and diabetes [109] while adiponectin has been shown 
to have beneficial effects on insulin sensitivity [24]. Thus, the relationship between SREBP1 and 
adiponectin remains to be elucidated in a future study. One study showed that the inhibition of SREBP-
1c by pioglitazone is adiponectin dependent [110] suggests that adiponectin might negatively regulate 
SREBP-1c.  
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                Also, we measured serum protein expression of ghrelin, pancreatic polypeptide, PYY, insulin, 
glucagon, leptin and adiponectin (Figure 19-Figure 26). No differences were seen in serum protein 
expression of ghrelin, pancreatic polypeptide, PYY, insulin, glucagon, leptin and adiponectin.  
                One limitation of our study is that we only measured serum protein level of these peripheral 
signals for one time point. The secretion and circulating levels of these peripheral signals are all 
influenced by recent energy intake and dietary macronutrient content, although circulating insulin and 
leptin concentrations are mainly proportional to body fat content [91]. Also, the circulating levels of 
many short term regulators of energy balance are time-dependent after a single meal. For example, 
post-prandially, the circulating PYY levels rise rapidly to a plateau after 1–2 h and remain elevated for up 
to 6 h [92].  
                One time point can’t reflect the whole picture of peripheral signals in response to different 
dietary fat types. Therefore, our data do not conclusively show that there is no effect of dietary fat type 
on peripheral signals of energy balance.  
The effect of dietary fat types on gut microbiota 
                In this study, we were interested the effect of dietary fatty acids on gut microbiota richness and 
β-diversity. We collected feces from rats and ran 16S rRNA of fecal microbiota analysis at the end of 
phase 1. We found that 36-day different fatty acid diet intervention did not change gut microbiota 
richness and β-diversity (Figure 8). However, we cannot exclude the possible effect of dietary fatty acids 
on the compositional pattern of gut microbiota. It was reported that lard-based high fat diet increased 
the abundance of the Mollicutes class of the Firmicutes phylum and reduced the abundance of 
Bacteroidetes [83]. But little has been reported of different fatty acids diet on gut microbiota 
compositional pattern, which remains to be clarified in a future study.  
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                In our study, qPCR analysis showed the PUFA diet increased ileum β-defensin 2 and β-defensin 
3 gene expression with and without antibiotic treatment (Figure 13). Β-defensins are components of 
endogenous antimicrobials which provide a first of line of defence against potentially pathogenic 
microbes at the body’s mucosal frontiers [46]. Thus, it is possible that the increased β-defensins 
associated with the PUFA diet is involved in modulate gut microbiota. However, as the secretion of β-
defensins is also in response to bacteria in the intestine, the real relationship between β-defensins, 
dietary fatty acids and gut microbiota remains to be clarified in a future study.  
                Recent work showed that β-defensins can bind to the MC4R to control feeding and body weight 
[48]. Intracerebroventricular injection of human β-defensin 3 to male Wistar rats has an inhibitory effect 
on both the food intake and body weight gain with the potential mechanism of blocking AgRP [49]. Thus, 
we measured serum total β-defensins level and β-defensin 14 (homologues of HBD3) [93]. No 
differences were seen between PUFA diet and SFA diet. Thus, on the basis of our study result, we 
speculate that different gene expression induced by different fatty acid diet didn’t have an effect on the 
circulating levels of β-defensins and these were not involved in the different effects of SFA diet and 
PUFA diet on energy balance.  
The effect of antibiotics on gut microbiota 
                Antibiotics are commonly used to modulate gut microbiota, providing an approach to 
investigate the causative role of the whole gut microbiota in the body energy balance in addition to 
germ-free mice [111]. In our study, we choose imipenem/cilastatin to modulate gut microtioa. 
Imipenem is usually administered intravenously in combination with cilastatin [112]. In vitro it has been 
demonstrated that imipenem has an extremely wide spectrum of antibacterial activity against Gram-
negative and Gram-positive aerobic and anaerobic bacteria, even against many multiresistant strains of 
bacteria [112]. On the basis of its poor systemic bioavailability, imipenem has a direct impact on the gut 
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microbiota, instead of host metabolic pathways [113]. Previously, it was reported that Wistar rats 
treated with imipenem/cilastatin 50 mg/kg body weight for 4 days had altered metabolite patterns in 
urine and feces [113]. In our pilot study, we compared 4-day antibiotic treatment and 7-day antibiotic 
treatment with two different methods: oral gavage or given in water. The results showed that 7-day 
antibiotic treatment given in water most successfully decreased gut microbiota in Sprague Dawley rats. 
Therefore, we chose to treat rats with 7-day imipenem/cilastatin given in water. As we expected, the 
results of 16s RNA gene sequencing showed that 7-day imipenem/cilastatin successfully knocked down 
gut microbiota (Figure 9).  
                However, the effect of antibiotic treatment on gut microbiota of rats with PUFA diet was 
smaller than with the SFA diet.  The 7-day antibiotic treatment significantly decreased gut microbiota 
richness about 50% on the SFA diet but only decreased 28.6% on the PUFA diet (Figure 9). The result 
indicated that the PUFA diet might protect gut microbiota from antibiotics due to the proinflammatory 
property of n-6 PUFA as our PUFA diet was safflower oil based high fat diet which was composed mainly 
of n-6 PUFA.  
The effect of knockdown of gut microbiota on body weight, food intake and energy 
expenditure 
 
                We were interested in the effect of knockdown of gut microbiota on energy balance. We 
recorded rats’ daily body weight and food intake during 7-day antibiotic or vehicle treatment. It showed 
that the knockdown of gut microbiota significantly decreased the food intake regardless of different 
dietary fatty acids (Figure 11 and Figure 12). Thus, based on this result, we speculated no association 
between dietary fatty acids and gut microbiota on food intake. 
                The result that decreasing gut microbiota decreased food intake in our study is consistent with 
many other studies [52, 114]. The effect of gut microbiota on food intake might be mediated by gut 
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hormones. Thus, we measured PYY and GLP-1 gene expression in ileum and colon, where the major 
colonization sites of gut microbiota are. However, we didn’t detect any difference between antibiotic or 
vehicle treatment on expression of these two genes in the two parts of the intestine.  Also, no 
differences were seen in serum protein expression of ghrelin, PP, PYY, insulin, glucagon, leptin and 
adiponectin between antibiotic or vehicle treatment. As the secretion and circulating levels of these 
peripheral signals are all influenced by recent energy intake and dietary macronutrient content as well 
as time-dependent after a single meal [91, 92], we cannot get the whole picture of these peripheral 
signals in response to antibiotic or vehicle treatment. This is a limitation of our study. In a future study, 
we will focus on these peripheral hormones levels at different time point after a meal during the study 
to investigate the effect of gut microbiota on peripheral signals to control food intake.  
                Also, we compared gene expression of β-defensins in ileum and colon as well as protein 
expression of total β-defensins and β-defensin 14 in serum between antibiotic and vehicle treatment. 
No significant differences were seen (Figure 15 and Figure 16). We speculate that β-defensins were not 
involved in the effect of gut microbiota on energy balance. In fact, β-defensins gene expression is very 
low in intestine [115]. Thus, the effect of gut microbiota on β-defensins might be too small to be 
detected. Also, the physiological levels of β-defensins might not have an effect on the regulation of 
energy balance. 
                As the knockdown of gut microbiota decreased food intake, we expected a less weight gain in 
rats treated with antibiotics than in those treated with vehicle. However, the knockdown of gut 
microbiota didn’t have an effect on body weight change (Figure 8).  
                One possible explanation is that the observation period was too short to see a significant 
weight change between antibiotic and vehicle treatment. Previously, it was reported that weight 
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difference was observed 28 days after the gut microbiota modified by berberine [116]. Another possible 
explanation is the adaptive thermogenesis change in response to the decreased food intake [117].  
Indications of current study and future directions 
                The results from our study supported the hypothesis that a SFA diet is more obesigenic than a 
PUFA diet due to the increased food intake. However, our study failed to discover the potential 
mechanism for rats to increase food intake on SFA diet as no differences were seen in serum protein 
expression of ghrelin, pancreatic polypeptide, PYY, insulin, glucagon, leptin and adiponectin. One 
limitation of our study is that we fail to look at different time points of the peripheral signals in response 
to the two different fatty acid diets, which should be improved in a future study.  
                The knockdown of gut microbiota reduced rats’ food intake regardless of dietary fatty acid 
indicates no association between gut microbiota and dietary fatty acid on energy balance. We tried to 
discover the potential mechanism linking gut microbiota and food intake. But no differences between 
antibiotic and vehicle treatment were seen in serum protein expression of ghrelin, pancreatic 
polypeptide, PYY, insulin, glucagon, leptin and adiponectin. As previously discussed, the only one time 
point measurement can’t reflect the whole picture of these peripheral hormones in response to gut 
microbiota change.  Thus, how gut microbiota influenced food intake remains to be clarified in a future 
study.  
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